Clinical Trials Logo

Cannabis Dependence clinical trials

View clinical trials related to Cannabis Dependence.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01598896 Terminated - Cannabis Dependence Clinical Trials

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

DCCS
Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia are more likely than healthy people to abuse cannabis. Cannabis use may worsen clinical outcomes in this group, making the identification of pharmacotherapy to treat cannabis dependence in those with schizophrenia important. The investigators intend to test the combination of dronabinol, a cannabinoid agonist, and the α2-adrenergic agonist clonidine, for cannabis dependence in subjects with schizophrenia. The combination of dronabinol and clonidine may alleviate cannabis withdrawal symptoms while allowing treatment-seeking outpatients to benefit from medical management (MM) sessions when they are trying to stop using cannabis. The investigators propose to assess the relationship of dronabinol and clonidine, when added to MM, on cannabis use patterns in cannabis-dependent patients with schizophrenia. Hypothesis: The investigators predict that combination pharmacotherapy of dronabinol and clonidine will significantly reduce cannabis use compared to those receiving placebo.

NCT ID: NCT01439828 Terminated - Cannabis Dependence Clinical Trials

Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

MUCOCRAV
Start date: February 2012
Phase: Phase 2
Study type: Interventional

The primary purpose is to assess the efficacy in human of N-acetylcysteine versus placebo during 4 weeks in cannabis withdrawal.